Review: Prospects for ARB in the next five years

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med 1987;316:1429-35.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med 1991;325:293-302.

Pfeffer MA , Braunwald E. , Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8.

Garg R. , Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6.

Kober L. , Torp-Pedersen C. , Carlsen JE et al.A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. NEnglJMed 1995;333:1670-6.

Yusuf S. , Lonn E. , Bosch J. , Gerstein H. Summary of randomized trials of angiotensin converting enzyme inhibitors . Clin Exp Hypertens 1999;21:835-45.

Flather MD , Yusuf S. , Kober L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.

Yusuf S. , Sleight P. , Pogue J. , Bosch J. , Davies R. , Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.Lancet 2001;358:1033-41. 11. Burnier M. , Brunner HR Angiotensin II receptor antagonists. Lancet 2000;355:637-45.

Pitt B. , Poole-Wilson PA , Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.

Pitt B. , Segal R. , Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) . Lancet 1997;349:747-52.

Dickstein K. , Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 1999;83:477-81.

Pfeffer MA , McMurray J. , Leizorovicz A. et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.

Carson PE Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. Am Heart J 2000;140:361-6.

Dickstein K. , Chang P. , Willenheimer R. et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. JAm Coll Cardiol 1995;26:438-45.

Di Pasquale P. , Bucca V. , Scalzo S. , Paterna S. Safety, tolerability, and neurohormonal changes of the combination captopril plus losartan in the early postinfarction period: a pilot study. Cardiovasc Drugs Ther 1998;12:211-16.

Hamroff G. , Katz SD , Mancini D. et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999;99:990-2.

Cohn JN , Tognoni G. , the Valsartan Heart Failure Trial Investigators. A Randomized Trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.

Cohn JN , Tognoni G. , Glazer R. , Spormann D. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators . Eur J Heart Fail 2000;2:439-46.

Swedberg K. , Pfeffer M. , Granger C. et al. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.J Card Fail 1999;5:276-82.

Bart BA , Ertl G. , Held P. et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999 ;20:1182-90.

Dahlof B. , Devereux R. , de Faire U. et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997;10:705-13.

Mann J. , Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-83.

Lewis EJ , Hunsicker LG , Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

Brenner BM , Cooper ME , de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.NEnglJMed 2001;345:861-9.

Parving HH , Lehnert H. , Brochner-Mortensen J. , Gomis R. , Andersen S. , Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.

Hansson L. , Lithell H. , Skoog I. et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999;8:177-83.